Philosys Healthcare Supplies COVID-19 Test Kits to Europe, Asia, and Africa

[Asia Economy Reporter Eunmo Koo] Philosis Healthcare announced on the 16th that it will supply the novel coronavirus disease (COVID-19) diagnostic kit ‘Gmate COVID-19’ to Italy, Switzerland, Egypt, and Malaysia.

This contract was signed respectively with Biogenic S.A (Switzerland·Italy), A&B Health Supplies SDN. BHD (Malaysia), and MED CARE EGYPT (Egypt). The contract scale is a total of 11.5 billion KRW over 3 years based on the minimum order amount.

Including this contract, the cumulative supply contract amount of Philosis Healthcare’s Gmate COVID-19 has reached 18.1 billion KRW, increasing the supply scale since the launch of Gmate COVID-19 on the 13th.

According to the company, with the acquired CE-IVD certification, sales are possible in countries within Europe, Asia, and Africa after a simple registration process. Approval from the U.S. Food and Drug Administration (FDA) is also being prepared.

A Philosis Healthcare official stated, “Existing immunodiagnostic methods had an accuracy below 85%, making them unsuitable for field use, but the new Gmate COVID-19 uses an antigen immunoassay method and shows 93% accuracy,” adding, “RT-PCR, which shows 95% accuracy, can vary depending on the experimenter and environment, but Gmate COVID-19 is hardly affected by external factors, so it is expected to be very helpful in the field.”

This content was produced with the assistance of AI translation services.